PTGS2 and colorectal carcinoma: Predictably, both celecoxib and rofecoxib use were demonstrated to be associated with a significant reduction in polyp recurrence at colonoscopy, compatible with a future role for selective COX-2 inhibitors in colorectal cancer (CRC) chemoprevention5–7.